文献速递肾癌与肾肿瘤

立体定向消融体部放疗在肾细胞癌中的作用

The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2022-07-14

本文为叙述性综述,检索PubMed 2000年1月至2021年12月文献,纳入2项荟萃分析(含54项研究)、13项前瞻性研究和20项回顾性研究,总结SABR在原发性及转移性肾细胞癌中的应用证据,包括局部控制、毒性及与系统治疗联合的安全性。

要点

  • SABR对原发性肾细胞癌局部控制率超过90%,3-4级毒性为0-9%。
  • 颅内转移性肾细胞癌SRS局部控制率为90%-97%。
  • 寡转移性肾细胞癌中SABR可延迟系统治疗至少1年者占70%-90%,3-4级毒性低于10%。

核心结论

  • SABR可用于原发性及转移性肾细胞癌的关键临床场景,包括替代系统治疗、与系统治疗联合以及脑和脊柱转移的姑息治疗。

研究设计与样本

  • 叙述性综述,在线检索PubMed数据库2000年1月至2021年12月文献,纳入靶向原发性、颅外或颅内转移性肾细胞癌的SABR/立体定向放射外科(SRS)研究。
  • 纳入2项荟萃分析(包含54项研究)、13项前瞻性研究和20项回顾性研究。

主要发现

  • SABR治疗575例患者的589个原发性肾细胞癌,局部控制率超过90%,3-4级毒性为0-9%。
  • SRS治疗1225例颅内转移性肾细胞癌患者,局部控制率为90%-97%。
  • SABR使70%-90%的寡转移性肾细胞癌患者延迟系统治疗至少1年,3-4级毒性低于10%。
  • 早期数据显示,SABR与系统治疗(如靶向治疗或免疫治疗)联合用于转移性肾细胞癌似乎安全、可行且可耐受。

临床怎么用

  • 作者总结支持SABR用于原发性和转移性肾细胞癌的关键临床场景,包括替代系统治疗、与系统治疗联合以及脑和脊柱转移的姑息治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Stereotactic ablative body radiotherapy (SABR) is an emerging treatment modality for primary and metastatic renal cell carcinoma (RCC). OBJECTIVE: To review and summarise the evidence on the use of SABR in RCC in a narrative review. EVIDENCE ACQUISITION: We performed an online search of the PubMed database from January 2000 through December 2021. Studies of SABR/stereotactic radiosurgery (SRS) targeting primary, extracranial, or intracranial metastatic RCC were included. EVIDENCE SYNTHESIS: Two meta-analyses (including 54 studies), and 13 prospective and 20 retrospective studies were included in this review. In aggregate, SABR for 589 primary RCCs in 575 patients resulted in a local control rate of above 90% with grade 3-4 toxicity of 0-9%. Similarly, the local control rate ranged between 90% and 97% with SRS in 1225 patients with intracranial metastatic RCC. SABR was able to delay systemic therapy for at least 1 yr in 70-90% of oligometastatic RCC patients with grade 3-4 toxicity of <10%. As per the early data, the combination of SABR with systemic therapy for metastatic RCC, such as targeted therapy or immunotherapy, appears safe, feasible, and tolerable. CONCLUSIONS: We outlined data supporting SABR in the key clinical scenarios of primary and metastatic, including oligometastatic, RCC in lieu of systemic therapy, in combination with systemic therapy, and palliation of brain and spinal metastases. PATIENT SUMMARY: Stereotactic ablative body radiotherapy (SABR) is a relatively new treatment option in kidney cancer. Here, we review the published literature on the experience of using SABR in kidney cancer. The accumulated evidence demonstrates that SABR can be used safely and effectively to treat selected cases of primary or secondary kidney cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ali M, Mooi J, Lawrentschuk N, et al. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Eur Urol. 2022. PMID: 35843777. doi:10.1016/j.eururo.2022.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。